Table 3.
Malignancy | Mouse strain | Age | Sex | Dosage | Fractionation | Latency | Spontaneous frequency | Induced frequency | Ref. |
---|---|---|---|---|---|---|---|---|---|
Lung Cancer | C3H (C3H/HeSlc) | 6 weeks | Male | 7.5 Gy thoracic | 2 doses, 12-h interval | 12 months | 3.5–9.5% | 40% | (232,233) |
Lung Cancer | RFM (RFM/Un) | 10–12 weeks | Female | 9 Gy thoracic | single | 9 months | ~28% | 87% | (235,236) |
Lung Cancer | BALB/c (BALB/c/An) | 12 weeks | Female | 2 Gy TBI | single | 12 months | ~12% | ~37% | (237,238) |